Clinical Trial Update: TAK-243 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes With Increased Blasts [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating TAK-243 for relapsed or refractory acute myeloid leukemia and myelodysplastic syndromes with increased blasts; currently recru…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia
• Myelodysplastic Syndrome
• Myelodysplastic Syndrome Acute Myeloid Leukemia
• Myelodysplastic Syndrome with Excess Blasts

Drugs mentioned

• TAK-243 (Ubiquitin-activating enzyme E1 inhibitor TAK-243)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Myelodysplastic Syndrome With Excess Blasts, Recurrent Acute Myeloid Leukemia | Phase 1 | Status: RECRUITING